-
Endo boosts portfolio with Qualitest acquisition
CHADDS FORD, Pa. Endo Pharmaceuticals will acquire generic drug maker Qualitest Pharmaceuticals for $1.2 billion, Endo said Tuesday.
Endo said the purchase of privately owned Qualitest would expand its offering of branded drugs, generics, devices and services in areas such as pain and urology. Qualitest is the sixth largest generic drug company in the United States, as measured by prescriptions filled.
-
Valeant, Biovail become one
MISSISSAUGA, Ontario The merger between Valeant Pharmaceuticals International and Biovail is complete, the two companies said Tuesday.
Shareholders of both companies have approved the merger, worth more than $3 billion, originally announced in June.
The combined company will take Valeant’s name.